Biomarkers in psychiatry – A critique

Annals of Neurosciences

Volumn 23, Issue 1, 2016, Pages 3-5

  Venkatasubramanian, Ganesan ^a   Keshavan, Matcheri S ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; GOLD STANDARD; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; MEDICAL RESEARCH; MENTAL DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUROIMAGING; NONHUMAN; NOTE; OUTCOME ASSESSMENT;

EID: 84961214864     PISSN: 09727531     EISSN: 09763260     Source Type: Journal    
DOI: 10.1159/000443549     Document Type: Note

References (29)

1. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA: Schizophrenia, 'just the facts': what we know in 2008 part 3: neurobiology. Schizophr Res 2008; 106: 89-107.
2. Turner JA: The rise of large-scale imaging studies in psychiatry. Gigascience 2014; 3: 29.
3. Deco G, Kringelbach ML: Great expectations: using whole-brain computational connectomics for understanding neuropsychiatric disorders. Neuron 2014; 84: 892-905.
4. Wright R, Réthelyi JM, Gage FH: Enhancing induced pluripotent stem cell models of schizophrenia. JAMA Psychiatry 2014; 71: 334-335.
5. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
6. Lakhan SE, Kramer A: Schizophrenia genomics and proteomics: are we any closer to biomarker discovery? Behav Brain Funct 2009; 5: 2.
7. Hager BM, Keshavan MS: Neuroimaging biomarkers for psychosis. Curr Behav Neurosci Rep 2015; 2: 102-111.
8. Prata D, Mechelli A, Kapur S: Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev 2014; 45: 134-141.
9. Wurtman R: Biomarkers in the diagnosis and management of Alzheimer's disease. Metabolism 2015; 64(3 suppl 1): S47-S50.
10. Goldani AA, Downs SR, Widjaja F, Lawton B, Hendren RL: Biomarkers in autism. Front Psychiatry 2014; 5: 100.
11. Kapur S, Phillips AG, Insel TR: Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012; 17: 1174-1179.
12. Andrews G, Brugha T, Thase ME, Duffy FF, Rucci P, Slade T: Dimensionality and the category of major depressive episode. Int J Methods Psychiatr Res 2007; 16(suppl 1): S41-S51.
13. Cuthbert BN: Research domain criteria: toward future psychiatric nosologies. Dialogues Clin Neurosci 2015; 17: 89-97.
14. Casey BJ, Craddock N, Cuthbert BN, Hyman SE, Lee FS, Ressler KJ: DSM-5 and RDoC: progress in psychiatry research? Nat Rev Neurosci 2013; 14: 810-814.
15. Keshavan MS, Ongur D: The journey from RDC/DSM diagnoses toward RDoC dimensions. World Psychiatry 2014; 13: 44-46.
16. Whalley HC, Papmeyer M, Sprooten E, Lawrie SM, Sussmann JE, McIntosh AM: Review of functional magnetic resonance imaging studies comparing bipolar disorder and schizophrenia. Bipolar Disord 2012; 14: 411-431.
17. Maze I, Shen L, Zhang B, Garcia BA, Shao N, Mitchell A, et al: Analytical tools and current challenges in the modern era of neuroepigenomics. Nat Neurosci 2014; 17: 1476-1490.
18. Frohlich J, Van Horn JD: Reviewing the ketamine model for schizophrenia. J Psychopharmacol 2014; 28: 287-302.
19. Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, et al: The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 2014; 5: 47.
20. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J: Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007; 20: 687-702.
21. Kalmady SV, Venkatasubramanian G, Shivakumar V, Gautham S, Subramaniam A, Jose DA, et al: Relationship between Interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naïve schizophrenia: evidence for differential susceptibility? PLoS One 2014; 9: e96021.
22. Xu K, Schadt EE, Pollard KS, Roussos P, Dudley JT: Genomic and network patterns of schizophrenia genetic variation in human evolutionary accelerated regions. Mol Biol Evol 2015; 32: 1148-1160.
23. Alawieh A, Zaraket FA, Li JL, Mondello S, Nokkari A, Razafsha M, et al: Systems biology, bioinformatics, and biomarkers in neuropsychiatry. Front Neurosci 2012; 6: 187.
24. Westerhoff HV, Palsson BO: The evolution of molecular biology into systems biology. Nat Biotechnol 2004; 22: 1249-1252.
25. Narayanan B, Ethridge LE, O'Neil K, Dunn S, Mathew I, Tandon N, et al: Genetic sources of subcomponents of event-related potential in the dimension of psychosis analyzed from the B-SNIP study. Am J Psychiatry 2015; 172: 466-478.
26. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium: Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 2015; 18: 199-209.
27. Anney RJ, Kenny EM, O'Dushlaine C, Yaspan BL, Parkhomenka E, Buxbaum JD, et al: Gene-ontology enrichment analysis in two independent family-based samples highlights biologically plausible processes for autism spectrum disorders. Eur J Hum Genet 2011; 19: 1082-1089.
28. Réthelyi JM, Benkovits J, Bitter I: Genes and environments in schizophrenia: the different pieces of a manifold puzzle. Neurosci Biobehav Rev 2013; 37: 2424-2437.
29. Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-293.